Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?-Reference-Cited by-同舟云学术

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Published:2023-07 Issue: Volume: Page:
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Santoni Matteo,Buti Sebastiano,Myint Zin W.,Maruzzo Marco,Iacovelli Roberto,Pichler Martin,Kopecky Jindrich,Kucharz Jakub,Rizzo Mimma,Galli Luca,Büttner Thomas,De Giorgi Ugo,Kanesvaran Ravindran,Fiala Ondřej,Grande Enrique,Zucali Paolo Andrea,Kopp Ray Manneh,Fornarini Giuseppe,Bourlon Maria T.,Scagliarini Sarah,Molina-Cerrillo Javier^ORCID,Aurilio Gaetano,Matrana Marc R.,Pichler Renate,Cattrini Carlo,Büchler Tomas,Massari Francesco,Seront Emmanuel,Calabrò Fabio,Pinto Alvaro,Berardi Rossana,Zgura Anca,Mammone Giulia,Ansari Jawaher,Atzori Francesco,Chiari Rita,Bamias Aristotelis,Caffo Orazio,Procopio Giuseppe,Sunela Kaisa,Bassanelli Maria,Ortega Cinzia,Grillone Francesco,Landmesser Johannes,Milella Michele,Messina Carlo,Küronya Zsófia,Mosca Alessandra,Bhuva Dipen,Santini Daniele,Vau Nuno,Morelli Franco,Incorvaia Lorena,Rebuzzi Sara Elena,Roviello Giandomenico,Soares Andrey,Bisonni Renato,Bimbatti Davide,Zabalza Ignacio Ortego,Rizzo Alessandro,Mollica Veronica,Sorgentoni Giulia,Monteiro Fernando Sabino M.,Battelli Nicola,Bracarda Sergio,Porta Camillo

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference17 articles.

1. EAU guidelines on renal cell carcinoma: 2014 update;Ljungberg;Eur Urol,2015

2. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries;Allemani;Lancet,2018

3. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

4. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Motzer;N Engl J Med,2019

5. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety;Urologic Oncology: Seminars and Original Investigations;2024-11

2. Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study);International Journal of Cancer;2024-09-07

3. Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab;Immunotherapy;2024-08-19

4. Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis;International Journal of Clinical Oncology;2024-08-07

5. Prognostic Role of Pre-Treatment Body Composition Parameters in Patients Undergoing First-Line Immunotherapy for Metastatic Renal Cell Carcinoma;Cancer Management and Research;2024-08